Research and Development Investment: Bausch Health Companies Inc. vs ImmunityBio, Inc.

R&D Investments: Bausch Health vs. ImmunityBio's Decade of Growth

__timestampBausch Health Companies Inc.ImmunityBio, Inc.
Wednesday, January 1, 20142460000001595000
Thursday, January 1, 201558280000011434000
Friday, January 1, 201645500000026546000
Sunday, January 1, 201736600000039778000
Monday, January 1, 201841400000053418000
Tuesday, January 1, 2019471000000111997000
Wednesday, January 1, 2020452000000139507000
Friday, January 1, 2021465000000195958000
Saturday, January 1, 2022529000000248149000
Sunday, January 1, 2023604000000232366000
Loading chart...

Unlocking the unknown

A Decade of Innovation: R&D Investments in the Pharmaceutical Sector

In the ever-evolving landscape of pharmaceuticals, research and development (R&D) investments are pivotal for innovation and growth. Over the past decade, Bausch Health Companies Inc. and ImmunityBio, Inc. have demonstrated contrasting strategies in their R&D expenditures. Bausch Health has consistently increased its R&D spending, peaking in 2023 with a 145% rise from 2014. This commitment underscores their focus on expanding their product pipeline and enhancing existing treatments. In contrast, ImmunityBio, Inc. has shown a remarkable growth trajectory, with R&D expenses surging by over 14,500% from 2014 to 2023. This dramatic increase highlights their aggressive pursuit of groundbreaking therapies, particularly in immunotherapy. As these companies continue to invest in R&D, they not only drive their own growth but also contribute significantly to advancements in healthcare, promising a future of innovative treatments and improved patient outcomes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025